Men being treated for hormone refractory prostate cancer are now being offered a new service at Peterborough City Hospital as part of a Prostate Cancer UK funded project.
The 18 month project will fund a dedicated community prostate cancer clinical nurse who will run clinics that provide support and ensure regular and timely follow-ups for patients.
The project aims to ensure that men receive ongoing support and encouragement through improved care, as well as offering them the opportunity to take part in the National Cancer Survivorship Initiative and ensuring they lead as healthy and active life as possible.
Hormone refractory prostate cancer is cancer that has become resistant to the effects of hormone therapy.
The hospital in Bretton is run by the Peterborough and Stamford Hospitals NHS Foundation Trust.
Claire Martin, community prostate cancer clinical nurse, said: “I am very excited to work with the Trust and Prostate Cancer UK on this new project which will be hugely beneficial to men.
“The new service will allow more time to focus on their holistic needs, which can have a detrimental effect upon the quality of life for patients and their families if not addressed.”
Tasia Malinowski, health and social care professionals programme manager at Prostate Cancer UK, said: “We’re delighted Claire has accepted the new prostate cancer clinical nurse post at Peterborough City Hospital.
“A diagnosis can turn a man’s world upside down in an instant and making sense of which treatments to choose or coming to terms with side effects can be incredibly daunting.
“However, over the next 18 months, Claire will be supporting men across the region every step of the way, through treatment and beyond.
“Prostate cancer is set to become the most common cancer overall by 2030, which is why Prostate Cancer UK is recruiting people to its Men United movement and is encouraging men to do something together to help beat the disease.”
The service will operate Monday to Thursday from 8am to 6pm and patients will be referred to the service by their Oncology Consultant.